Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib + HS-10296 in EGFR-mutated advanced NSCLC
CTR20191893Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famitinib, almonertinib in EGFR-mutated non-small cell lung cancer, sponsored by Hengrui Therapeutics. Started Oct 2019; status: active.
02
Drugs
famitinibalmonertinib
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on CTR20191893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191893.